MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options and Restricted Stock Units
ROCKVILLE, MD, October 18, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 14 October 2024, Cynthia Collins, a non-executive director, has been granted total of 97,698 options ("Option Grant") in respect of common stock in the Company ("Common Stock"), and 51,679 restricted stock units ("RSU"s), which were agreed in September pursuant to Cynthia's appointment.
The Option Grant vests over three (3) years, with the initial vesting of 1/3rd of the total after twelve (12) months, and the remainder vesting monthly over the following 24 months. The Option Grant have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 14 October 2024, of $3.87 on the United States Nasdaq Stock Exchange.
The RSUs vest at the end of twelve (12) months after date of grant. (1 year cliff until fully vested).
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400
|
| Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|
UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
| a)
| Name
| Cynthia Collins | |
| 2
| Reason for the notification
| ||
| a)
| Position/status
| Non-Executive Director | |
| b)
| Initial notification /Amendment
| Initial notification | |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||
| a)
| Name
| MaxCyte, Inc. | |
| b)
| LEI
| 54930053YHXULRFCU991 | |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
| a)
| Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |
| | | ||
| Identification code | US57777K1060 | ||
| | | ||
| b)
| Nature of the transaction
| Grant of options of common stock | |
| c)
| Price(s) and volume(s) | 97,698 Options at an exercise price of $3.87 | |
| d)
| Aggregated information | | |
| | | ||
| - Aggregated volume | N/A | ||
| | | ||
| - Price | N/A | ||
| | | ||
| e)
| Date of the transaction
| 14 October 2024 | |
| f)
| Place of the transaction
| US Stock Exchange, Nasdaq | |
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
| a)
| Name
| Cynthia Collins | |
| 2
| Reason for the notification
| ||
| a)
| Position/status
| Non-Executive Director | |
| b)
| Initial notification /Amendment
| Initial notification | |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||
| a)
| Name
| MaxCyte, Inc. | |
| b)
| LEI
| 54930053YHXULRFCU991 | |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
| a)
| Description of the financial instrument, type of instrument | Grant of restricted stock units | |
| | | ||
| Identification code | US57777K1060 | ||
| | | ||
| b)
| Nature of the transaction
| Grant of options of restricted stock units | |
| c)
| Price(s) and volume(s) | 51,679 restricted stock units, price N/A | |
| d)
| Aggregated information | | |
| | | ||
| - Aggregated volume | N/A | ||
| | | ||
| - Price | N/A | ||
| | | ||
| e)
| Date of the transaction
| 14 October 2024 | |
| f)
| Place of the transaction
| US Stock Exchange, Nasdaq | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.